



Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

July 29, 2026

MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.

The webcast will be available on Liquidia's website at <https://liquidia.com/investors/events-and-presentations>. A rebroadcast of the event will be available and archived for a period of one year at the same location.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT[®] technology. PRINT enabled the development of YUTREPIA[®] (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Investors:

Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com

Media:

media@liquidia.com

